Clinton Would Give $300M More to Breast Cancer Research
Clinton Would Give $300M More to Breast Cancer Research
Appearing on the "The Ellen DeGeneres Show," Democratic presidential hopeful Sen. Hillary Clinton is not ready to throw in the towel. Instead, she said that fighting off the boys made her tough and that she would give another $ 300 million a year to breast cancer research.

"I know your mom is a survivor, and we've lost my incredible mother-in-law to breast cancer during Bill's first term and first year in office, and I've just been really committed," Clinton said on The Ellen DeGeneres Show. "I've had so many friends, and we all know people who survived and people who haven't. And I just think we should set a goal of curing breast cancer within the next decade," Clinton said.

About the delicate issue of giving up as she slides behind Barack Obama in the race to become the Democratic presidential candidate, Clinton said that she will not give up yet.

"You know, boys used to say that to me all the time," Hillary Clinton replied. "And I figured I know this contest is close. I don’t think either one of us should get out. We should let people vote. There are a lot of states that haven’t voted yet. They deserve a chance to have their votes counted," Clinton said.

Last month, US researchers have reported that letrozole, an oral non-steroidal aromatase inhibitor that blocks the production of estrogen, is effective in preventing the relapse of breast cancer even if it's taken years later than previously thought.

The initial FDA approval for letrozole, known by its brand name Femara, targeted the use of the estrogen blocking drug within three months after treatment with another cancer drug, Tamoxifen. It was previously thought that if Femara would be taken later it would have little influence on the cancer relapse rates.

In fact, the new research showed stunning effectiveness of almost 60 percent in cutting the relapse rate if taken beyond the three-month window. There is also a 50 percent reduction of death rate, a 61 percent reduction of metastasis rate and a 82 percent reduction of the risk to develop cancer in the other breast.



© 2007 - 2009 - eNews 2.0 All Rights Reserved
 
 
 
 



 

dotclear
dotclear